Medical writer covering 18 specialties- but specializing in just one: Alzheimer's.

Search Tweets

Twitter Feed

@Alz_Gal — 318 followers, 508 tweets

Nov 21, 2017

@Dreesenkl They will not wait for the extension study to finish, according to Missling. if the phase 2/3 goes ahead it may overlap with the extension study. This is not uncommon. #Aducanumab is doing a similar thing right now.

Nov 21, 2017

#CTAD17 #CTAD2015 #Anavex 2-73 presses forward based on positive cognitive findings in 6 patients. Phase 2/3 trial should be announced by the end of this year, CEO Christopher Missling says. https://t.co/TSOZrxs4qG

Nov 21, 2017

#CTAD17 #CTAD2015 #Anavex 2-73 presses forward based on positive cognitive findings in 6 patients. Phase 2/3 trial should be announced by the end of this year, CEO Christopher Missling says. https://t.co/TSOZrxs4qG

Nov 20, 2017

#CTAD17 #CTAD2017 #Anavex 2-73 story should be posted this evening. I will link to it as soon as it is.

Nov 16, 2017

@TTTav66 @TTTav66 Take a good long look at those slides, on the website slide 23, 24 and 29 in particular.

Show More